Form 4: AEHR Board Member Boosts Stake with New RSU Grant
Rhea-AI Filing Summary
Aehr Test Systems (AEHR) director Rhea J. Posedel has filed a Form 4 reporting the grant of 10,575 restricted stock units (RSUs) on 07/02/2025. The RSUs carry no cash exercise price and will vest in equal eighths at the end of each three-month period, contingent on continued board service. Following the award, the director’s direct ownership rises to 71,163 shares, while an additional 470,977 shares are held indirectly through a trust, bringing total beneficial ownership above 542,000 shares.
The filing also references earlier ESOP plan distributions that are already reflected in the current share count and do not constitute new market transactions. No derivative securities were exercised or disposed of, and there were no open-market purchases or sales disclosed. While RSU grants are routine board compensation, the increased equity stake further aligns the director’s interests with shareholders.
- Transaction type: RSU award (code “A”)
- Shares acquired: 10,575
- Total direct shares after grant: 71,163
- Total indirect shares: 470,977 (via trust)
- Vesting: 1/8 every three months
No price was paid for the RSUs, and the filing is unlikely to be materially market-moving on its own, though it signals continued long-term commitment from a key board member.
Positive
- Director acquired 10,575 RSUs, modestly increasing direct ownership.
- Total beneficial stake now exceeds 542,000 shares, underscoring alignment with shareholders.
Negative
- None.
Insights
TL;DR Director received 10,575 RSUs; ownership tops 542 k shares—routine but mildly positive alignment signal.
The Form 4 shows a standard board compensation grant rather than an opportunistic market purchase. Although these RSUs come at no cost, they increase Posedel’s direct stake to 71,163 shares and total beneficial holdings to roughly 0.2 % of AEHR’s outstanding shares (assuming ~270 M shares). Investors typically view growing insider ownership as a governance positive, but the absence of cash outlay limits signaling power. The vesting schedule ties the director to a three-year horizon, modestly reinforcing long-term alignment. No red flags—no sales, no derivative exercises. Overall impact: neutral to slightly positive, not a major valuation catalyst.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 10,575 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- One-eighth (1/8) of the total number of shares subject to the restricted stock unit awards shall vest at the end of each three full calendar months following the date of this action, provided that such recipient still serves as a member of the Board of Director of the corporation on such dates. The amount reported includes shares subject to unvested restricted stock units. Mr. Rhea Posedel received a required minimum distribution from ESOP plan for CY 2024 of 3,408 shares on 11/04/2024. The closing price was $11.23 per share. Mr. Rhea Posedel received a required minimum distribution from ESOP plan for CY 2025 of 1,409 shares on 4/2/2025. The closing price was $7.84 per share. Mr. Rhea Posedel received 18,115 shares due to the termination of the Company's ESOP plan on 04/25/2025. The closing price was $8.76 per share.
